Nykode Therapeutics ASA

Quick facts

Marketed products

• Atezolizumab Injection [Tecentriq] · Oncology
  Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.

Phase 2 pipeline

• VB10.16

Phase 1 pipeline

• VB10.2129
• VB10.2210
• VB10.NEO

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Nykode Therapeutics ASA portfolio CI brief
• Nykode Therapeutics ASA pipeline updates RSS